buspirone
Adjunctive therapy • Brands: BUSPAR
Last reviewed: 2025-12-28
General information
- Class: Adjunctive therapy
- Common US brands: BUSPAR
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-28
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Non-benzodiazepine anxiolytic; 5-HT1A partial agonist (azapirone).
Metabolism & Half‑life
- Metabolism: CYP3A4
- Half‑life: Single-dose range 2–3 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Buspirone hydrochloride prescribing information — DailyMed (2025)
- Evidence-based pharmacological treatment of anxiety disorders — Depression and Anxiety (2014)
- Azapirones for generalized anxiety disorder — The Cochrane Database of Systematic Reviews (2006)
- Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care — International Journal of Psychiatry in Clinical Practice (2012)